0.5849  0.036 (6.6%)		01-23 16:00
Open: 0.5525 High: 0.5938 Volume: 106,816		Pre. Close: 0.5487 Low: 0.5525 Market Cap: 12(M)

Short term
Mid term
Targets	6-month :	0.74	1-year :	0.87
Resists	First :	0.63	Second :	0.74
Pivot price	0.57
Supports	First :	0.54	Second :	0.49
MAs	MA(5) :	0.54	MA(20) :	0.56
	MA(100) :	0.7	MA(250) :	1.12
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	41.6	D(3) :	34.6
RSI	RSI(14): 51.8
52-week	High :	1.91	Low :	0.49

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ LGVN ] has closed below upper band by 41.1%. Bollinger Bands are 22.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.6 - 0.6	0.6 - 0.6
Low:	0.55 - 0.55	0.55 - 0.55
Close:	0.58 - 0.59	0.59 - 0.59

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Sun, 21 Dec 2025
Is Longeveron Stock Built to Withstand More Downside? - Trefis

Tue, 02 Dec 2025
Longeveron (NASDAQ: LGVN) gets Canada patent on LOMECEL-B for frailty and NIDCM - Stock Titan

Mon, 01 Dec 2025
Longeveron (NASDAQ: LGVN) sees MRI inflammation drop in 13 of 14 brain regions at week 39 - Stock Titan

Wed, 12 Nov 2025
Longeveron announces resignations of two board members - Investing.com

Tue, 04 Nov 2025
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Mon, 03 Nov 2025
Earnings To Watch: Longeveron Inc (LGVN) Reports Q3 2025 Result - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	20 (M)
Held by Insiders	1.606e+007 (%)
Held by Institutions	14.8 (%)
Shares Short	1,350 (K)
Shares Short P.Month	0 (K)

EPS	-2.098e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-5 %
Return on Assets (ttm)	335.7 %
Return on Equity (ttm)	-61 %
Qtrly Rev. Growth	1.44e+006 %
Gross Profit (p.s.)	-411.5
Sales Per Share	-599.6
EBITDA (p.s.)	5.4e+006
Qtrly Earnings Growth	-1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-17 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	0.24

Dividend	0
Forward Dividend	979700
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.